Gemcitabine + Oxaliplatin
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mixed Mullerian Tumors of the Uterus
Conditions
Mixed Mullerian Tumors of the Uterus
Trial Timeline
Aug 1, 2006 → Dec 1, 2015
NCT ID
NCT00476086About Gemcitabine + Oxaliplatin
Gemcitabine + Oxaliplatin is a phase 2 stage product being developed by Sanofi for Mixed Mullerian Tumors of the Uterus. The current trial status is completed. This product is registered under clinical trial identifier NCT00476086. Target conditions include Mixed Mullerian Tumors of the Uterus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00674206 | Phase 2 | Terminated |
| NCT00456599 | Phase 2 | Completed |
| NCT00476086 | Phase 2 | Completed |
| NCT00256295 | Phase 2 | Terminated |
| NCT00436800 | Phase 2 | Completed |
Competing Products
20 competing products in Mixed Mullerian Tumors of the Uterus